Greykasell Wealth Strategies Inc. Makes New $169,000 Investment in Gilead Sciences, Inc. $GILD

Greykasell Wealth Strategies Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 1,528 shares of the biopharmaceutical company’s stock, valued at approximately $169,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares during the period. Finally, Nuveen LLC purchased a new position in Gilead Sciences in the 1st quarter worth about $620,415,000. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Morgan Stanley raised their target price on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Truist Financial restated a “buy” rating and issued a $145.00 target price (up previously from $127.00) on shares of Gilead Sciences in a report on Monday, November 3rd. Finally, Needham & Company LLC raised their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $129.13.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at $12,855,329.01. This represents a 2.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 94,646 shares of company stock worth $11,311,286. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 0.7%

Shares of NASDAQ:GILD opened at $124.09 on Tuesday. The firm has a fifty day moving average of $117.61 and a two-hundred day moving average of $113.02. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $127.68. The firm has a market capitalization of $153.96 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the company earned $2.02 earnings per share. Gilead Sciences’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.